|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 4,687,659
U.S. Patent 4,687,659, granted on August 18, 1987, to Eli Lilly and Company, covers a method of synthesizing and using a specific class of compounds known as selective serotonin reuptake inhibitors (SSRIs). The patent primarily claims the chemical structure of the compounds, their synthesis processes, and their therapeutic application in treating depression and related disorders.
What Is the Scope of the Patent Claims?
Claims Breakdown:
The patent includes 27 claims divided into the following categories:
-
Chemical Structure Claims:
- Cover specific chemical compounds characterized as SSRIs with a common core structure, notably fluoxetine (Prozac) and related analogs.
- Claim 1 broadly claims a class of compounds with a specific formula, encompassing various substitutions at designated positions.
-
Synthesis Methods:
- Claims detail synthetic routes for preparing the compounds, including key intermediates and reaction conditions.
-
Therapeutic Use:
- Claims specify the use of these compounds in the treatment of depression, obsessive-compulsive disorder, and other psychiatric conditions.
Scope Analysis:
- The chemical structure claims are broad, covering not only fluoxetine but also a wide class of analogs with similar core features.
- The claims are specific about substituents, yet the language allows for a range of modifications, giving the patent a relatively broad scope.
- Use claims are narrower, emphasizing specific therapeutic applications.
Key Claims and Their Implications
| Claim Type |
Specifics |
Implication |
| Chemical structure |
Covering a class of compounds with a core structure and variable substitutions |
Grants exclusivity over a broad molecular class, enabling patent holders to deter generic competition for similar SSRIs |
| Synthesis method |
Specific steps to produce the compounds, including reaction conditions |
Protects processes used by the patent owner, potentially blocking generic manufacturing if identical or similar processes are employed |
| Therapeutic use |
Use in treating depression and other psychiatric disorders |
Enforces patent rights over the utilization of the compounds in specific medical indications |
Patent Landscape and Legal Status
Expiration and Patent Lifespan
- The patent was filed in 1984 and granted in 1987.
- It had a standard 20-year term from filing, expiring in 2004, assuming all maintenance fees were paid.
- The patent's expiration opened the field for generic manufacturers to produce SSRIs similar to fluoxetine.
Related Patents and Continuations
- Several related patents from Eli Lilly extend and reinforce exclusivity, including process patents and method-of-use patents.
- For instance, related patents (e.g., U.S. Patent 4,962,118) cover formulations and specific usage claims.
- Patent families include filings in other jurisdictions, reinforcing the global IP protection strategy.
Patent Challenges and Litigation
- No notable patent litigations directly challenging U.S. Patent 4,687,659 are publicly documented.
- Market entry by generics post-expiration aligned with open competition, with some efforts to patent specific formulations or uses.
- Generic companies such as Barr Labs and Teva launched fluoxetine products after the patent expired.
Contemporary Patent Strategies and Overlaps
Post-expiration intellectual property:
- Patent holders often pursue new patents covering specific formulations or dosing regimens.
- Patents on methods of treatment or new uses continue to extend the commercial landscape even after primary patents expire.
- Co-development and patent thickets secure market dominance.
Overlap with other SSRIs:
- Patents on other SSRIs (e.g., paroxetine, sertraline) have similar structure-function claims.
- Companies use narrow claims to defend individual molecules while broad claims remain open for competitors.
Regulatory Exclusivities:
- Data exclusivity periods provide additional market protection beyond patent terms.
- FDA grants market exclusivity for certain indications, impacting generic entry.
Summary of the Patent Landscape
| Aspect |
Details |
| Patent expiration |
2004 (for the core compound) |
| Related patents |
Extended protection via process, formulation, and use patents |
| Litigation history |
Limited publicly available challenges |
| Patent strategies |
Focus on formulation patents, new uses, and delivery methods post-expiration |
Key Takeaways
- U.S. Patent 4,687,659 broadly claims structural analogs of fluoxetine, blocking generics during its active term.
- The patent's expiration in 2004 led to increased generic market entry for fluoxetine.
- Patent families and related applications extend Eli Lilly's exclusive rights via process, formulation, and use patents.
- The landscape includes strategic patenting around formulations and indications to prolong market exclusivity.
- Recent patents focus on novel delivery systems or specific patient populations, not the original compound.
FAQs
1. How broad are the chemical claims of U.S. Patent 4,687,659?
They cover a large class of SSRIs with similar core structures and variable substitutions, enabling the patent holder to exclude many analogs from the market during the patent life.
2. What was the patent's impact on generic fluoxetine producers?
The patent prevented generic competition until its expiration in 2004, after which generics entered the market widely.
3. Are there newer patents that extend the protection of fluoxetine or similar drugs?
Yes. Patents on formulations, specific uses, and delivery methods have been filed post-2004 to extend market protection.
4. Has this patent been involved in litigation?
There are no documented major litigations challenging the patent directly, but market dynamics shifted upon its expiration.
5. How does the patent landscape for SSRIs compare globally?
Similar patents exist in other jurisdictions, with varying durations and scope. Patent families often include filings in Europe, Japan, and other key markets.
Sources:
- U.S. Patent and Trademark Office (USPTO). "Patent Grant 4,687,659."
- Eli Lilly. Patent family filings and related patent applications.
- Federal Trade Commission reports on patent expiration and market entry.
- Market data on generic fluoxetine launched post-2004.
- Patent litigation databases, Westlaw and LexisNexis.
More… ↓
⤷ Start Trial
|
